OPK Stock Risk & Deep Value Analysis
OPKO Health Inc
Healthcare • Diagnostics & Research
DVR Score
out of 10
What You Need to Know About OPK Stock
We analyzed OPKO Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran OPK through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is OPK Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for OPK?
- ⚠
Lower-than-expected Ngenla/Skytrofa sales or market adoption
- ⚠
Continued high cash burn leading to further significant shareholder dilution
- ⚠
Negative clinical trial results for pipeline assets
- ⚠
Increased competitive pressure in the hGH market
Unlock OPK Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does OPKO Health Inc (OPK) Do?
Market Cap
$1.01B
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,997
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
Visit OPKO Health Inc WebsiteIs OPK Stock Undervalued?
Unlock the full AI analysis for OPK
Get the complete DVR score, risk analysis, and more
Does OPK Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Expanding
Moat Sources
2 Identified
The patent protection for Somatrogon and the robust global distribution network provided by Pfizer establish a durable, albeit specialized, competitive advantage within the long-acting hGH market for the foreseeable future. This moat is tied directly to the success and exclusivity of Ngenla/Skytrofa.
Moat Erosion Risks
- •Emergence of next-generation, more convenient or effective hGH therapies from competitors.
- •Patent expiration for Somatrogon in key markets.
- •Weakening or underperformance of the Pfizer partnership in certain regions.
OPK Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive OPK Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Release (Estimated late Feb/early March 2026)
- •Updates on Ngenla/Skytrofa global market penetration and sales figures (via Pfizer disclosures)
Medium-Term (6-18 months)
- •Further Ngenla/Skytrofa country approvals and launches in key markets (6-18 months)
- •Progress updates on other pipeline assets, e.g., Rayaldee expansion or clinical trial advancements
Long-Term (18+ months)
- •Ngenla/Skytrofa reaching peak sales potential and becoming a significant royalty revenue stream
- •Strategic shift towards sustainable profitability or non-dilutive financing
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for OPK?
- ✓
Acceleration in Ngenla/Skytrofa sales growth reported by Pfizer and corresponding royalty revenue increases for OPKO.
- ✓
Demonstrable and sustained reduction in OPKO's quarterly cash burn.
- ✓
Any announcements of non-dilutive financing or significant asset divestitures.
- ✓
Positive clinical trial readouts for other key pipeline assets.
Bull Case Analysis
See what could go right with Premium
Compare OPK to Similar Stocks
See how OPKO Health Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for OPK (OPKO Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
